Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02226900
Other study ID # MERGING
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date August 2014

Study information

Verified date November 2018
Source InCor Heart Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a pilot randomized study that aim to assess the safety and feasibility of a hybrid myocardial revascularization strategy (coronary artery by-pass graft and percutaneous intervention) in comparison with conventional surgical coronary bypass grafting.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 60
Est. completion date
Est. primary completion date December 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Triple-vessel disease with proximal or mid LAD disease with angiographic diameter stenosis > 70% by visual analysis in all three territories, requiring myocardial revascularization OR triple-vessel disease with proximal or mid LAD disease with angiographic diameter stenosis 50-70% by visual analysis in any territory but with invasive or non-invasive evidence of flow-limiting stenosis in all three territories, requiring myocardial revascularization

- Total SYNTAX score > 22

- LCx and RCA territories estimated to be equivalently revascularized by either PCI or CABG, with at least one major non-LAD vessel to be treated

- Clinical and anatomic eligibility for both PCI and CABG as agreed to by both interventional and surgical consensus

- Interventionalist determines PCI appropriateness and eligibility

- Surgeon determines surgical appropriateness and eligibility

- Silent ischemia, stable angina, unstable angina or recent MI

- If recent MI, cardiac biomarkers must have returned to normal prior to randomization

- Ability to sign informed consent and comply with all study procedures

Exclusion Criteria:

- Prior PCI or CABG at any time prior to randomization

- Need for any concomitant cardiac surgery other than CABG (e.g. valve surgery, aortic repair, etc.), or intent that if the patient randomizes to surgery, any cardiac surgical procedure other than isolated CABG will be performed

- Patients unable to tolerate, obtain or comply with dual antiplatelet therapy for at least one year

- Patients requiring additional surgery (cardiac or non cardiac) within one year

- The presence of any clinical or anatomical condition(s) which leads the participating interventional cardiologist to believe that clinical equipoise is not present (i.e. the patient should not be treated by PCI, but rather should be managed with CABG or medical therapy - reasons will be documented)

- The presence of any clinical or anatomical condition(s) which leads the participating cardiac surgeon to believe that clinical equipoise is not present (i.e. the patient should not be treated by CABG, but rather should be managed with PCI. or medical therapy - reasons will be documented)

- Non cardiac co-morbidities with life expectancy less than 1 year

- Other investigational drug or device studies that have not reached their primary endpoint.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Hybrid Revascularization
Off-pump LIMA connected to the left anterior descending artery followed by percutaneous coronary intervention with drug eluting stents to the other territories.
Conventional Coronary Artery Bypass Surgery
On pump coronary artery by-pass surgery

Locations

Country Name City State
Brazil InCor -Faculdade de Medicina da Universidade de São Paulo São Paulo SP

Sponsors (2)

Lead Sponsor Collaborator
InCor Heart Institute Boston Scientific Corporation

Country where clinical trial is conducted

Brazil, 

Outcome

Type Measure Description Time frame Safety issue
Other Quality of life. 5 years
Other Cost Evaluate and compare the final cost of the procedure and follow up period of the patients enrolled in each one of the strategies. 5 years
Other Hospital Stay Evaluate and compare the period of hospital stay of the patients enrolled in each one of the strategies. 1 year
Primary Feasibility of Revascularization Procedure Proposed by the Heart Team The primary endpoint of this pilot study is the feasibility of revascularization planned preoperatively by the Heart team in the absence of adverse events (death, myocardial infarction, stroke, or unplanned revascularization) at 30 days. 30 days
Secondary Major Adverse Cardiovascular Events Composite and isolated measure of adverse events (all-cause death, myocardial infarction, stroke, or unplanned revascularization) at 1 year and annually up to 5 years. 1 year
Secondary Major Adverse Cardiovascular Events Composite and isolated measure of adverse events (all-cause death, myocardial infarction, stroke, or unplanned revascularization) at 1 year and annually up to 5 years. 2 years
Secondary Major Adverse Cardiovascular Events Composite and isolated measure of adverse events (all-cause death, myocardial infarction, stroke, or unplanned revascularization) at 1 year and annually up to 5 years. 3 years
Secondary Major Adverse Cardiovascular Events Composite and isolated measure of adverse events (all-cause death, myocardial infarction, stroke, or unplanned revascularization) at 1 year and annually up to 5 years. 4 years
Secondary Major Adverse Cardiovascular Events Composite and isolated measure of adverse events (all-cause death, myocardial infarction, stroke, or unplanned revascularization) at 1 year and annually up to 5 years. 5 years
Secondary Major Adverse Cardiovascular Events Composite and isolated measure of adverse events (all-cause death, myocardial infarction, stroke, or unplanned revascularization) at 1 year and annually up to 5 years. 180 days
Secondary Safety Cause of death (cardiac vs. non-cardiac); MI type; stroke type and severity. 1 year
Secondary Recurrence of Angina Analyse patient recurrence of angina according to the Canadian Cardiovascular Society (CCS) 1 year
Secondary Medication Impact Impact of antithrombotic agents and dual antiplatelet therapy in peri-procedural and long-term follow up safety end points. 1 year
Secondary Stent Thrombosis Evaluate stent thrombosis according to the ARC (Academic Research Consortium) criteria 1 year
Secondary Bleeding Hemorrhagic complications according to the BARC (Bleeding Academic Research Consortium) criteria 1 year
Secondary Neurological Events Evaluate neurological complications by clinical tests (physical examination), vascular ultrasound and doppler perfusion measures. 1 year
Secondary Graft Patency Patency of grafts and coronary artery disease at 1 year of follow-up evaluated by angiotomography 1 year
Secondary Clinical and Angiographic Scores Correlation with Prognostic Evaluate the clinical correlation between the revascularization strategy and the usefulness of the SYNTAX score, ACEF score, clinical SYNTAX score, logistic EuroSCORE, STS score and InsCor for prognostic evaluation 1 year
Secondary Efficacy of the Strategy Evaluate and compare the rate of repeated revascularization (target lesions and target vessels) in each one of both strategies. 1 year
Secondary Symptomatic Graft Occlusion Evaluate patients that presented with recurrent ischaemia symptoms due to graft occlusion. The diagnostic must be done by angiography or angiotomography. 1 Year
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05669222 - The FAVOR V AMI Trial N/A
Not yet recruiting NCT06025071 - Residual Inflammatory Risk-Guided colcHicine in Elderly Trial Phase 4
Recruiting NCT05786131 - Complete Revascularization Versus Culprit Lesion Only PCI in NSTEMI N/A
Recruiting NCT06168305 - Safety and Effectiveness of GENOSS DES in Patients With Multivessel Coronary Artery Disease
Not yet recruiting NCT05835167 - Complete Revascularization Via Inferior Part-sternotomy N/A
Completed NCT01881555 - Functional Testing Underlying Coronary Revascularisation N/A
Not yet recruiting NCT06400290 - Multivessel Balloon Occlusion to Investigate Obstructive Coronary Artery Disease and aNgina N/A
Active, not recruiting NCT01621438 - Clinical Implication of 3-vessel Fractional Flow Reserve (FFR) N/A
Not yet recruiting NCT06378775 - Robotically-assisted Minimally-invasive Direct Coronary Artery Bypass With Stenting, Randomized Against Coronary Artery Bypass Graft Surgery N/A
Completed NCT05125367 - Ten-Year Outcomes of Randomized Comparison of Coronary Artery Bypass Surgery and Everolimus-Eluting Stent Implantation in the Treatment of Patients With Multivessel Coronary Artery Disease
Completed NCT01947439 - Comparison of the Biolimus A9-eluting Stent With the Zotarolimus -Eluting Stent in Multi-vessel PCI N/A
Recruiting NCT05333068 - COMBINE-INTERVENE: COMBINEd Ischemia and Vulnerable Plaque Percutaneous INTERVENtion to Reduce Cardiovascular Events N/A
Withdrawn NCT03851276 - A Multicentre, Pilot Study to Evaluate the Safety and the Feasibility of Planning and Execution of Surgical Revascularization in Patients With Complex Coronary Artery Disease, Based Solely on MSCT Imaging Utilizing GE Healthcare Revolution CT and HeartFlow FFRCT. Phase 4
Completed NCT02813473 - SYNTAX III REVOLUTION Trial: A Randomized Study Investigating the Use of CT Scan and Angiography of the Heart to Help the Doctors Decide Which Method is the Best to Improve Blood Supply to the Heart in Patients With Complex Coronary Artery Disease
Recruiting NCT05698719 - Validation of vFFR as Compared to FFR to Guide Revascularization of Non-culprit Lesions in STEMI Patients
Completed NCT01399736 - Comparison Between FFR Guided Revascularization Versus Conventional Strategy in Acute STEMI Patients With MVD. N/A
Not yet recruiting NCT01311323 - Revascularization Strategies in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome (NSTE-ACS) and Severe Coronary Artery Disease N/A
Completed NCT00818792 - Randomized Comparison of xiEnce and visioN Coronary Stents in the sAme muLtivessel Patient With Chronic kiDnEy diSease Phase 2
Completed NCT01199419 - Cost-effectiveness of PCI With Taxus vs CABG - 5 Years FUP N/A
Completed NCT04743154 - In-hospital Versus After-discharge Complete Revascularization N/A